Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Summary

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Conditions

• Stage IB Lung Non-Small Cell Carcinoma AJCC v7
• Stage II Lung Non-Small Cell Cancer AJCC v7
• Stage IIA Lung Cancer AJCC v8
• Stage IIB Lung Cancer AJCC v8
• Stage IIIA Lung Cancer AJCC v8
• Stage IIIA Lung Non-Small Cell Cancer AJCC v7
• Stage IIIB Lung Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

DRUG

Carboplatin

Given IV

DRUG

Cisplatin

Given IV

OTHER

Clinical Observation

Undergo observation

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

DRUG

Crizotinib

Given PO

OTHER

Cytology Specimen Collection Procedure

Undergo collection of blood and tissue

PROCEDURE

Echocardiography Test

Undergo ECHO

DRUG

Erlotinib

Given PO

DRUG

Gemcitabine Hydrochloride

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Pemetrexed

Given IV

DRUG

Pemetrexed Disodium

Given IV

OTHER

Placebo Administration

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• David E Kozono · Alliance for Clinical Trials in Oncology

Study Design

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-09-26

Primary Completion

2026-09-28

Completion

2026-09-28

FDA Drug

Yes

Countries

• United States
• Guam
• Puerto Rico

Study Locations